公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司之附屬公司北京加科思就其訂立的 許可及合作協議，已收到阿斯利康支付的1億美元的首付款。該首付款的到賬，進一步充 盈了本集團的現金儲備，也將為本集團後續創新腫瘤療法管線研發的推進提供助力。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 加科思收到阿斯利康就泛KRAS抑制劑JAB-23E73訂立的許可及合作協議項下 的1億美元首付款 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 茲提述本公司日期為2025年12月21日的公告，內容有關北京加科思新藥研發有限公司（「北 京 ...

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly focusing on those with promising pipelines and market potential [14]. Core Insights - The innovative drug sector in China is experiencing high-quality growth in research and development, significantly outpacing global averages. This trend positions China as a key player in the global innovative drug market [10]. - The medical device sector is seeing a recovery in bidding scales and a shift towards innovation, with companies like Mindray Medical and Aohua Endoscopy being highlighted for their growth potential [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like BGI Genomics and Nanwei Technology being recommended for investment [17]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being noted as key players [18]. Summary by Sections Market Review - The medical index rose by 1.49%, outperforming the CSI 300 index by 2.9 percentage points, ranking fifth among 30 sectors [7]. - Top-performing stocks included Meinuohua and Wanbangde, while stocks like Keyuan Pharmaceutical and Changyao Tui faced significant declines [30]. Innovative Drugs - The report emphasizes the importance of innovative drugs, with a focus on companies like BeiGene and Hengrui Medicine, which are expected to benefit from global market expansion [10][14]. - The collaboration between companies like JAK-23E73 and AstraZeneca is highlighted as a significant advancement in the innovative drug pipeline [14]. Medical Devices - The report notes a recovery in the medical device sector, with a focus on high-value consumables and the internationalization of domestic companies [15]. - Companies such as Mindray Medical and Aohua Endoscopy are recommended for their innovative products and growth potential in both domestic and international markets [15]. Life Sciences Services - The life sciences service sector is expected to see a recovery in demand, with companies like BGI Genomics and Bioplus being highlighted for their growth potential [17]. - The report indicates that the sector's profitability is expected to improve as revenue growth resumes [17]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being recommended for investment [18]. - The report suggests that the integration of online and offline pharmacy services will enhance competitiveness [18]. Traditional Chinese Medicine - The report highlights the potential for growth in traditional Chinese medicine, particularly in basic drug categories and state-owned enterprise reforms [21]. - Companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical are recommended for their strong market positions [21]. Medical Services - The report suggests that the medical services sector will benefit from anti-corruption measures and the expansion of private healthcare, with companies like Gushengtang and Aier Eye Hospital being noted for their growth potential [20]. Blood Products - The report indicates that the blood products sector is expected to see growth due to relaxed approval processes and increasing demand, with companies like Tiantan Biological Products being highlighted [12].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 不適用 第一章節註釋： 公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 | 佔有關事件前的 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2026年3月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

Core Viewpoint - The MSCI China Healthcare Index has increased by 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5% [1] Industry Summary - The pharmaceutical industry has recently experienced a notable correction, particularly in the innovative drug sector, which has seen a significant decline [1] - The government's work report has identified biomedicine as an emerging pillar industry, leading to a mild recovery in risk appetite within the sector [1] - The elevation of policy positioning indicates a transition of the pharmaceutical industry from a "strategic emerging industry" to an "emerging pillar industry," suggesting that policy benefits across the entire value chain will continue to be released [1] - Breakthroughs in AI drug development technology, combined with the expansion of Chinese innovative drugs into overseas business development, are expected to create a dual resonance that accelerates the improvement of the industry's fundamentals [1] Company Recommendations - The following companies are recommended for purchase, with target prices set at: - Innovent Biologics (01801) - HKD 110.62 [1] - 3SBio (01530) - HKD 37.43 [1] - JACOB (01167) - HKD 10.34 [1] - Genscript Biotech (02273) - HKD 44.95 [1] - WuXi AppTec (02268) - HKD 88 [1]

Group 1 - The MSCI China Healthcare Index has increased by 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5% [1] - The pharmaceutical industry has recently experienced a significant pullback, particularly in the innovative drug sector [1] - The government's work report has identified biomedicine as an emerging pillar industry, leading to a moderate recovery in risk appetite for the sector [1] Group 2 - The policy shift indicates a transition of the pharmaceutical industry from a "strategic emerging industry" to an "emerging pillar industry," suggesting that policy benefits across the entire value chain will continue to be released [1] - Breakthroughs in AI drug development technology and the expansion of Chinese innovative drugs into overseas business development are creating a dual resonance effect, with expectations for an accelerated improvement in the industry's fundamentals [1] - The company recommends buying shares in Innovent Biologics (01801), 3SBio (01530), JACOBY (01167), Genscript Biotech (02273), and WuXi AppTec (02268), with target prices of HKD 110.62, HKD 37.43, HKD 10.34, HKD 44.95, and HKD 88 respectively [1]